Assessment of the Impact of a Meningitis/Encephalitis Panel on Hospital Length of Stay

Decorative image of the AMR Learning Lounge

Assessment of the Impact of a Meningitis/Encephalitis Panel on Hospital Length of Stay

SUMMARY

In conjunction with University of Texas Health (UTH), a multidisciplinary team, including several bioMérieux scientists, reviewed data about the impact of the BioFire® FilmArray® Meningitis/Encephalitis (ME) Panel for PCR testing on hospital length of stay (LOS) and days of antibiotic therapy. Findings from the systematic review of available research suggest that the multiplex ME panel is associated with a significant reduction in LOS and a potential reduction of the number of days of antibiotic therapy, supporting UTH antimicrobial stewardship efforts.

FEATURED EXPERTS

Tristan Timbrook, PharmD, Director of Health Economics Outcomes Research at bioMérieux

Kyle D. Hueth, Sr. Manager, Global Medical Affairs Scientist at bioMérieux

GET STARTED

Read the study at MDPI.

Take me there now!

Read time: 20 minutes

We want to hear from you!

Your feedback helps us continue to provide resources and content specific to your needs.

Take Our Poll

Global Solutions

BIOFIRE^® FILMARRAY^® Meningitis/Encephalitis Panel

The BIOFIRE ME Panel provides answers on 14 of the most common bacterial, viral, and yeast pathogens that cause central nervous system infections to help healthcare providers rapidly distinguish between bacterial and viral meningitis and optimize life-saving therapy.

Learn More